Enliven Therapeutics
ELVN
46.53
+0.12
+0.26%
Enliven Therapeutics
US · ELVN
#2416 by market cap
Listed 1970
46.53
+0.12
+0.26%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About Enliven Therapeutics
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.
- Founded
- 2019
- CEO
- Mr. Richard A. Fair
- Employees
- 60
- Headquarters
- Burlingame, California, United States of America
- Fiscal year end
- 12-31
- Website
- enliventherapeutics.com
Company profile
- Exchange
- US
- Symbol
- ELVN
- Market-cap rank
- #2416
- Listing date
- 1970-01-01
- Market cap
- 3.42B
- Float cap
- 3.02B
- Shares out
- 73.60M
- Float shares
- 64.84M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Enliven Therapeutics discussion 0 comments